Al Jalila Children’s Specialized Hospital announced the provision of gene therapy to an Egyptian child with spinal muscular atrophy, and an improvement in the child’s ability to move as a result of this treatment.
Rashid’s first visit to the hospital was 12 months ago, and he had not yet completed his first year, and since then he has been undergoing treatment with “Zolgensma” injections. The medical team evaluated Rashid’s physical and functional condition a year after starting the treatment, which showed an improvement in the movement of his upper limbs.
Dr. Haitham Al Bashir, Consultant Pediatric Neurological Rehabilitation, Head of the Center of Excellence in Neuroscience at Al Jalila Children’s Hospital, expressed his happiness with Rashid’s progress, as he can now move his shoulders up while sitting, and move from a lying to a sitting position with minimal assistance. from his hips, and on his knees for at least five minutes, as he began to crawl.
Dr. Al-Bashir explained – coinciding with the month of August to raise awareness of spinal muscular atrophy – that diagnosis and treatment in the early stages of the disease leads to better treatment results.. Pointing out that the disease can cause a decline in some of the skills that children have acquired because they become weaker over time, and that it It puts them at great risk, as muscle deterioration is so rapid that it can affect breathing and swallowing, potentially life-threatening for children.
Al Jalila Children’s Specialty Hospital launched Zulgensma treatment two years ago, and so far it has been provided to 41 patients from 13 countries across Europe and the Middle East, the largest proportion of whom are from Turkey.
#Jalila #Hospital #Positive #results #genetic #treatment #child #spinal #muscular #atrophy